Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity-Reference-Cited by-同舟云学术

Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity

Published:2021-07-21 Issue:12 Volume:62 Page:2921-2927
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shimony Shai¹²^ORCID,Bar-Sever Einat¹²,Berger Tamar¹²,Itchaki Gilad¹²^ORCID,Gurion Ronit¹²,Yeshurun Moshe¹²,Lahav Meir¹²,Raanani Pia¹²,Wolach Ofir¹²^ORCID

Affiliation:

1. Rabin Medical Center, Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Petah-Tikva, Israel

2. Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1948037

Reference33 articles.

1. Late-Onset Neutropenia After Rituximab Treatment

2. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

3. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma

4. Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab

5. Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Cureus;2024-01-10

2. Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients;Eye;2023-09-25

3. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study;Annals of Hematology;2023-06-19

4. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06

5. Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Life;2023-05-28